On June 3, 2020 AlivaMab Discovery Services, LLC, a leader in comprehensive, integrated solutions for antibody drug discovery, reported a discovery partnership with Tanabe Research Laboratories USA, Inc. (TRL, San Diego, California), an independent subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. ADS will provide its expertise and capabilities to generate and deliver therapeutic antibody candidates to TRL using the AlivaMab Mouse, a best-in-class antibody discovery platform (Press release, AlivaMab Discovery Services, JUN 3, 2020, View Source [SID1234560815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The proven expertise of ADS combined with the speed and efficiency with which AlivaMab Mouse can produce drug-quality antibodies is foundational for this collaboration" said John "Lippy" Lippincott, PhD, Vice-President of Research. "ADS has developed a track record of successfully delivering antibody drug candidates against challenging projects in a greater number and in shorter timelines than other organizations. We are pleased that TRL has entrusted ADS as a partner in using precision science to create breakthrough biological therapies."